Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis

J Chen, L Jian, Y Guo, C Tang, Z Huang, J Gao - Antioxidants, 2024 - mdpi.com
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-
third of the global population. MASLD and its advanced-stage liver fibrosis and cirrhosis are …

Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue

A Savino, A Loglio, F Neri, S Camagni… - Journal of Clinical …, 2024 - mdpi.com
The development of steatotic liver disease after liver transplant (LT) is widely described, and
epidemiological data have revealed an increased incidence in recent times. Its evolution …

Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population

NWS Chew, XH Pan, B Chong, C Chandramouli… - Diabetes Research and …, 2024 - Elsevier
The metabolic syndrome, characterized by type 2 diabetes mellitus (T2DM), hypertension,
hyperlipidemia, and obesity, collectively increases the risk of cardiovascular diseases …

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality

N Tamaki, T Kimura, SI Wakabayashi… - Alimentary …, 2024 - Wiley Online Library
Background A multi‐society consensus group proposed a new nomenclature for steatotic
liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease …

Low thyroid function is associated with metabolic dysfunction‐associated steatotic liver disease

S Wang, D Xia, H Fan, Z Liu, R Chen, C Suo… - JGH …, 2024 - Wiley Online Library
Abstract Background and Aim Metabolic dysfunction‐associated steatotic liver disease
(MASLD) is recently introduced to better highlight the pathogenic significance of …

Systemic metabolic Abnormalities: Key drivers of complications and mortality in MASLD

X Fan, B Zhang, Y Shi, L Liu… - Journal of Hepatology, 2024 - journal-of-hepatology.eu
Metabolic dysfunction-associated steatotic liver disease (MASLD), as a new term that
includes hepatic steatosis and cardiometabolic risk factors, has triggered numerous clinical …

The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis

G Kong, G Cao, J Koh, SP Chan… - Diabetes, Obesity …, 2024 - Wiley Online Library
Aim Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are at
increased risk of incident cardiovascular disease. However, the clinical characteristics and …

Prognostic effect of triglyceride glucose-related parameters on all-cause and cardiovascular mortality in the United States adults with metabolic dysfunction-associated …

Y Min, X Wei, Z Wei, G Song, X Zhao, Y Lei - Cardiovascular Diabetology, 2024 - Springer
Backgrounds Insulin resistance (IR) plays a vital role in the pathogenesis of the metabolic
dysfunction-associated steatotic liver disease (MASLD). However, it remains unclear …

A high reticulocyte count is a risk factor for the onset of metabolic dysfunction-associated steatotic liver disease: Cross-sectional and prospective studies of data of …

PC Ma, QM Li, RN Li, C Hong, H Cui… - Frontiers in …, 2024 - frontiersin.org
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD)
poses a considerable health risk. Nevertheless, its risk factors are not thoroughly …

Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic …

M Gurun, P Brennan, S Handjiev, A Khatib, D Leith… - Plos one, 2024 - journals.plos.org
Background and aims Metabolic dysfunction associated steatotic liver disease (MASLD)
increases the risk of incident chronic kidney disease (CKD). However, the relative risk of …